{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:03:31Z","timestamp":1777374211002,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.intimp.2022.109348","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:09:39Z","timestamp":1666703379000},"page":"109348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"PA","title":["The immunomodulatory effects of roflumilast on tachyzoite-bradyzoite transition in a murine model of Toxoplasma gondii"],"prefix":"10.1016","volume":"113","author":[{"given":"Ahlam","family":"Elmasry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafaa A.","family":"Aboukamar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heba","family":"Hany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manar S.","family":"Elmehankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.intimp.2022.109348_b0005","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","article-title":"Toxoplasma gondii: from animals to humans","volume":"30","author":"Tenter","year":"2000","journal-title":"Int. J. Parasitol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109348_b0010","doi-asserted-by":"crossref","first-page":"e90203","DOI":"10.1371\/journal.pone.0090203","article-title":"Toxoplasmosis\u2013a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries","volume":"9","author":"Flegr","year":"2014","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2022.109348_b0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1574-6968.2002.tb11323.x","article-title":"Monocyte chemotactic protein-1 secretion and expression after Toxoplasma gondii infection in vitro depend on the stage of the parasite","volume":"214","author":"Brenier-Pinchart","year":"2002","journal-title":"FEMS Microbiol. Lett."},{"issue":"24","key":"10.1016\/j.intimp.2022.109348_b0020","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1056\/NEJM196512092732404","article-title":"Isolation of the encysted form of Toxoplasma gondii from human skeletal muscle and brain","volume":"273","author":"Remington","year":"1965","journal-title":"New Engl. J. Med."},{"issue":"suppl_1","key":"10.1016\/j.intimp.2022.109348_b0025","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/jpids\/piu077","article-title":"Congenital Toxoplasmosis","volume":"3","author":"McAuley","year":"2014","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"issue":"2","key":"10.1016\/j.intimp.2022.109348_b0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.pt.2016.10.007","article-title":"Lifelong Persistence of Toxoplasma Cysts: A Questionable Dogma?","volume":"33","author":"Rougier","year":"2017","journal-title":"Trends Parasitol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109348_b0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1471-4922(02)02248-1","article-title":"Toxoplasma gondii tachyzoite-bradyzoite interconversion","volume":"18","author":"Lyons","year":"2002","journal-title":"Trends Parasitol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109348_b0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1128\/IAI.69.1.148-153.2001","article-title":"Cyclic nucleotide signaling in Toxoplasma gondii bradyzoite differentiation","volume":"69","author":"Kirkman","year":"2001","journal-title":"Infect. Immun."},{"issue":"4","key":"10.1016\/j.intimp.2022.109348_b0045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","article-title":"The preclinical pharmacology of roflumilast\u2013a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease","volume":"23","author":"Hatzelmann","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2022.109348_b0050","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1574-6976.2011.00305.x","article-title":"Mechanisms of Toxoplasma gondii persistence and latency","volume":"36","author":"Sullivan","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2022.109348_b0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clinthera.2011.12.008","article-title":"Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease","volume":"34","author":"Pinner","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.intimp.2022.109348_b0060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/978-3-642-17969-3_20","article-title":"Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases","volume":"204","author":"Shakur","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"issue":"14","key":"10.1016\/j.intimp.2022.109348_b0065","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.4155\/fmc-2018-0592","article-title":"Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis","volume":"11","author":"Sebasti\u00e1n-P\u00e9rez","year":"2019","journal-title":"Future Med. Chem."},{"issue":"18","key":"10.1016\/j.intimp.2022.109348_b0070","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1016\/j.bmc.2019.06.027","article-title":"Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors","volume":"27","author":"de Heuvel","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.intimp.2022.109348_b0075","first-page":"4","volume":"63","author":"de Ara\u00fajo","year":"2019","journal-title":"Imidazole Derivatives as Promising Agents for the Treatment of Chagas Disease"},{"key":"10.1016\/j.intimp.2022.109348_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2019.107793","article-title":"The phosphodiesterase-4 inhibitor roflumilast impacts Schistosoma mansoni ovipositing in vitro but displays only modest antischistosomal activity in vivo","volume":"208","author":"Botros","year":"2020","journal-title":"Exp. Parasitol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109348_b0085","doi-asserted-by":"crossref","first-page":"e22492","DOI":"10.1371\/journal.pone.0022492","article-title":"Identification of Toxoplasma gondii cAMP dependent protein kinase and its role in the tachyzoite growth","volume":"6","author":"Kurokawa","year":"2011","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.intimp.2022.109348_b0090","first-page":"185","article-title":"Repurposing drugs for the treatment and control of helminth infections, International journal for parasitology","volume":"4","author":"Panic","year":"2014","journal-title":"Drugs Drug Resistance"},{"issue":"1","key":"10.1016\/j.intimp.2022.109348_b0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1124\/jpet.115.229641","article-title":"Roflumilast Increases Bacterial Load and Dissemination in a Model of Pseudomononas Aeruginosa Airway Infection","volume":"357","author":"Kasetty","year":"2016","journal-title":"J. Pharmacol. Experim. Therap."},{"issue":"12","key":"10.1016\/j.intimp.2022.109348_b0100","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1017\/S0031182010000661","article-title":"Increased pregnancy weight gain in women with latent toxoplasmosis and RhD-positivity protection against this effect","volume":"137","author":"Ka\u0148kov\u00e1","year":"2010","journal-title":"Parasitology"},{"issue":"2","key":"10.1016\/j.intimp.2022.109348_b0105","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/CMR.11.2.267","article-title":"Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts","volume":"11","author":"Dubey","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.intimp.2022.109348_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40478-016-0293-8","article-title":"Chronic Toxoplasma gondii infection enhances \u03b2-amyloid phagocytosis and clearance by recruited monocytes","volume":"4","author":"M\u00f6hle","year":"2016","journal-title":"Acta Neuropathol Commun"},{"issue":"52","key":"10.1016\/j.intimp.2022.109348_b0115","doi-asserted-by":"crossref","first-page":"87351","DOI":"10.18632\/oncotarget.13568","article-title":"Activation of chronic toxoplasmosis by transportation stress in a mouse model","volume":"7","author":"Shen","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.intimp.2022.109348_b0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.exppara.2011.03.014","article-title":"Direct evidence of Toxoplasma-induced changes in serum testosterone in mice","volume":"128","author":"Ka\u0148kov\u00e1","year":"2011","journal-title":"Exp. Parasitol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109348_b0125","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/BF01690096","article-title":"Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice","volume":"15","author":"Araujo","year":"1996","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.109348_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2019.107756","article-title":"Biological evaluation of newly synthesized quinoline\u2013based compound PPQ-8 in acute and chronic toxoplasmosis: An experimental study","volume":"206","author":"Elgawad","year":"2019","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.intimp.2022.109348_b0135","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1128\/IAI.69.5.3413-3417.2001","article-title":"Immunohistochemical Analysis of Cellular Infiltrate and Gamma Interferon, Interleukin-12, and Inducible Nitric Oxide Synthase Expression in Leprosy Type 1 (Reversal) Reactions before and during Prednisolone Treatment","volume":"69","author":"Little","year":"2001","journal-title":"Infect. Immun."},{"issue":"6","key":"10.1016\/j.intimp.2022.109348_b0140","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-3083.2000.00817.x","article-title":"Cytokines involved in Toxoplasmic encephalitis","volume":"52","author":"Sarciron","year":"2000","journal-title":"Scand J Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2022.109348_b0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpara.2008.08.002","article-title":"The immunobiology of the innate response to Toxoplasma gondii","volume":"39","author":"Miller","year":"2009","journal-title":"Int. J. Parasitol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109348_b0150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/sj.icb.7100038","article-title":"Cytokine regulation of immunopathology in toxoplasmosis","volume":"85","author":"Gaddi","year":"2007","journal-title":"Immunol. Cell Biol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109348_b0155","doi-asserted-by":"crossref","first-page":"e45440","DOI":"10.1371\/journal.pone.0045440","article-title":"Interferon-\u03b3 restricts Toxoplasma gondii development in murine skeletal muscle cells via nitric oxide production and immunity-related GTPases","volume":"7","author":"Tak\u00e1cs","year":"2012","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.intimp.2022.109348_b0160","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4049\/jimmunol.165.2.628","article-title":"Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii","volume":"165","author":"Yap","year":"2000","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109348_b0165","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0147-9571(02)00058-9","article-title":"Pathogenesis of toxoplasmosis","volume":"26","author":"Bhopale","year":"2003","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2022.109348_b0170","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.arbres.2017.10.007","article-title":"Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease","volume":"54","author":"P\u00e9rez de Llano","year":"2018","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.intimp.2022.109348_b0175","first-page":"239","article-title":"Vasodilators and nitric oxide synthase","author":"Westfall","year":"1998","journal-title":"Human Pharmacol. Mol. Clin."},{"key":"10.1016\/j.intimp.2022.109348_b0180","doi-asserted-by":"crossref","unstructured":"M.A. Hortua Triana, K.M. M\u00e1rquez-Nogueras, S.A. Vella, S.N.J. Moreno, Calcium signaling and the lytic cycle of the Apicomplexan parasite Toxoplasma gondii, Biochimica et biophysica acta. Molecular cell research 1865(11 Pt B) (2018) 1846-1856.","DOI":"10.1016\/j.bbamcr.2018.08.004"},{"key":"10.1016\/j.intimp.2022.109348_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2020.102337","article-title":"The role of potassium and host calcium signaling in Toxoplasma gondii egress","volume":"94","author":"Vella","year":"2021","journal-title":"Cell Calcium"},{"issue":"1","key":"10.1016\/j.intimp.2022.109348_b0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1734-1140(12)70744-2","article-title":"Modulation of Th1\/Th2 cytokine production by selective and nonselective phosphodiesterase inhibitors administered to mice","volume":"64","author":"Szczypka","year":"2012","journal-title":"Pharmacol. Rep. : PR"},{"issue":"6","key":"10.1016\/j.intimp.2022.109348_b0195","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cellsig.2004.12.010","article-title":"Regulatory mechanisms and their therapeutic implications of interleukin-12 production in immune cells","volume":"17","author":"Kang","year":"2005","journal-title":"Cell. Signal."},{"issue":"2","key":"10.1016\/j.intimp.2022.109348_b0200","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1006\/clim.2000.4964","article-title":"The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo","volume":"98","author":"Beshay","year":"2001","journal-title":"Clin. Immunol. (Orlando Fla.)"},{"issue":"7","key":"10.1016\/j.intimp.2022.109348_b0205","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.autrev.2010.02.012","article-title":"Phosphodiesterase inhibitors in the management of autoimmune disease","volume":"9","author":"Shenoy","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2022.109348_b0210","first-page":"e921319","article-title":"Roflumilast, a Phosphodiesterases-4 (PDE4) Inhibitor, Alleviates Sepsis-induced Acute Kidney Injury","volume":"26","author":"Xu","year":"2020","journal-title":"Med. Sci. Monitor : Int. Med. J. Experim. Clin. Res."},{"issue":"3","key":"10.1016\/j.intimp.2022.109348_b0215","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/00912700222011328","article-title":"The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo","volume":"42","author":"Timmer","year":"2002","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109348_b0220","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.pupt.2005.09.002","article-title":"Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors","volume":"19","author":"Wollin","year":"2006","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2022.109348_b0225","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.2147\/DDDT.S165161","article-title":"Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap","volume":"12","author":"Zhang","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2022.109348_b0230","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1128\/IAI.69.3.1454-1462.2001","article-title":"Interleukin-12 promotes pathologic liver changes and death in mice coinfected with Schistosoma mansoni and Toxoplasma gondii","volume":"69","author":"Araujo","year":"2001","journal-title":"Infect. Immun."},{"issue":"4","key":"10.1016\/j.intimp.2022.109348_b0235","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.4049\/jimmunol.156.4.1476","article-title":"Contribution of nitric oxide to the host parasite equilibrium in toxoplasmosis","volume":"156","author":"Hayashi","year":"1996","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109348_b0240","first-page":"2031","article-title":"Involvement of apoptosis and interferon-gamma in murine toxoplasmosis","volume":"42","author":"Shen","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2022.109348_b0245","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/clin.1993.1062","article-title":"Activated microglia inhibit multiplication of Toxoplasma gondii via a nitric oxide mechanism","volume":"67","author":"Chao","year":"1993","journal-title":"Clin. Immunol. Immunopathol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109348_b0250","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4049\/jimmunol.152.3.1246","article-title":"Human microglial cell defense against Toxoplasma gondii. The role of cytokines","volume":"152","author":"Chao","year":"1994","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109348_b0255","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1128\/IAI.69.9.5573-5576.2001","article-title":"Gamma interferon-induced inhibition of Toxoplasma gondii in astrocytes is mediated by IGTP","volume":"69","author":"Halonen","year":"2001","journal-title":"Infect. Immun."},{"issue":"4","key":"10.1016\/j.intimp.2022.109348_b0260","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s12639-015-0712-y","article-title":"In vivo effect of anti-TNF agent (etanercept) in reactivation of latent toxoplasmosis","volume":"40","author":"El-Sayed","year":"2016","journal-title":"J. Parasitic Dis. : Off. Organ Ind. Soc. Parasitol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109348_b0265","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1286-4579(02)01537-X","article-title":"Toxoplasma gondii: in vivo expression of BAG-5 and cyst formation is independent of TNF p55 receptor and inducible nitric oxide synthase functions","volume":"4","author":"Silva","year":"2002","journal-title":"Microbes Infect."},{"issue":"2","key":"10.1016\/j.intimp.2022.109348_b0270","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.intimp.2022.109348_b0275","unstructured":"DALIRESP. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022522s009lbl.pdf?fbclid=IwAR2GrhW09UMuD1CeySXZwKEAwRjphmlXjXEtVCdIfG9Q-wSA2f0GNWEw-m0."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922008323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922008323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:00:56Z","timestamp":1761588056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922008323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":55,"alternative-id":["S1567576922008323"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109348","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunomodulatory effects of roflumilast on tachyzoite-bradyzoite transition in a murine model of Toxoplasma gondii","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109348"}}